Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00344981 · ClinicalTrials.gov registry record · NA

Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression

A NA study of HIV Infections and AIDS, sponsored by University of Maryland, Baltimore.

Completed
Registry status
NA
Development phase
9
Enrollment target
1
Study location

NCT00344981 is a NA study of HIV Infections and AIDS that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 9 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00344981, a NA study of HIV Infections and AIDS, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
NA
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

Study Hypothesis Evaluation of the durability of the combination Tenofovir and Hydroxyurea to maintain viral suppression below 50 copies/ml in volunteers who have achieved viral suppression on a standard HAART regimen.

Conditions Studied

Interventions

  • DRUG Hydroxyurea
  • DRUG Tenofovir

Study Locations (1)

Maryland

  • University of Maryland, Institute of Human Virology - Baltimore

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2003-06
Est. Completion 2006-11
Phase NA

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT00344981

The ClinicalTrials.gov registry entry for NCT00344981 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Hydroxyurea is the first listed.

NCT00344981 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00344981 about?

NCT00344981 is a clinical study titled "Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression". Study Hypothesis Evaluation of the durability of the combination Tenofovir and Hydroxyurea to maintain viral suppression below 50 copies/ml in volunteers who have achieved viral suppression on a standard HAART regimen.

What is the current status of trial NCT00344981?

This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2003-06. Estimated completion is 2006-11.

What conditions does trial NCT00344981 study?

This clinical trial studies the following conditions: HIV Infections, AIDS.

What interventions are being tested in trial NCT00344981?

The interventions under investigation include: Hydroxyurea (DRUG), Tenofovir (DRUG).

Who is sponsoring clinical trial NCT00344981?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00344981 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.